Ascletis' Subcutaneous PD-L1 Antibody ASC22 Demonstrated Potential of Functional Cure of Chronic Hepatitis B as 42.9% of Patients with Baseline HBsAg≤100 IU/mL Obtained Sustained HBsAg Loss
–Ascletis presented Phase IIb clinical trial results of subcutaneous PD-L1 antibody ASC22 for functional cure of CHB at…